Genetic Technologies (ASX:GTG) Short-Term Debt: A$0.64 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Short-Term Debt?

Genetic Technologies ASX:GTG Short-Term Debt is A$0.64 Mil as of Jun. 2024.

Genetic Technologies's Short-Term Debt for the quarter that ended in Jun. 2024 was A$0.64 Mil.

Genetic Technologies's quarterly Short-Term Debt stayed the same from Dec. 2023 (A$0.00 Mil) to Mar. 2024 (A$0.00 Mil) but then increased from Mar. 2024 (A$0.00 Mil) to Jun. 2024 (A$0.64 Mil).

Genetic Technologies's annual Short-Term Debt stayed the same from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.64 Mil).

Genetic Technologies Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Genetic Technologies Short-Term Debt Related Terms

Genetic Technologies Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Short-Term Debt Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.64

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.64 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.64 Mil mean?
Genetic Technologies (ASX:GTG) has a Short-Term Debt of A$0.64 Mil as of Jun. 2024.
Is Genetic Technologies' Short-Term Debt too high?
Genetic Technologies' current Short-Term Debt is A$0.64 Mil.
How does Genetic Technologies' Short-Term Debt compare to LDDD and NOTV?
Genetic Technologies' Short-Term Debt of A$0.64 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Genetic Technologies's current Short-Term Debt is A$0.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Short-Term Debt of A$0.64 Mil. The current Short-Term Debt is A$0.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Short-Term Debt is A$0.64 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.